Table 1. Baseline characteristics between participants who survived and those who died during follow-up.
| Characteristics | Total | Not died during follow-up | Died during follow-up |
| Data are presented as n (%). COPD: chronic obstructive pulmonary disease; Class 1 showed low multimorbidity, with prevalent chronic conditions like cancer, chronic liver disease, and COPD, etc. Class 2 had moderate multimorbidity, with chronic kidney disease, diabetes, and both hemorrhagic and ischemic strokes. Class 3 had high multimorbidity, primarily with atrial fibrillation, valvular heart disease, pulmonary heart disease, and cardiomyopathy. | |||
| Number of participants | 76,455 | 68,205 | 8,250 |
| Age, yrs | 73 (68–79) | 72 (68–78) | 81 (75–86) |
| Sex | |||
| Men | 38,489 (50.3%) | 33,931 (49.8%) | 4,558 (55.3%) |
| Women | 37,966 (49.7%) | 3,4274 (50.3%) | 3,692 (44.8%) |
| Marital status | |||
| Not married | 316 (0.4%) | 263 (0.4%) | 53 (0.6%) |
| Married | 73,941 (96.7%) | 66,055 (96.9%) | 7,886 (95.6%) |
| Divorced/other | 2,198 (2.9%) | 1,887 (2.8%) | 311 (3.8%) |
| Year of admission | |||
| 2016 | 9,331 (12.1%) | 7,371 (10.8%) | 1,960 (23.8%) |
| 2017 | 8,890 (11.5%) | 7,529 (11.0%) | 1,361 (16.5%) |
| 2018 | 10,565 (13.7%) | 9,178 (13.5%) | 1,387 (16.8%) |
| 2019 | 13,032 (16.6%) | 11,638 (17.1%) | 1,394 (16.9%) |
| 2020 | 11,179 (14.8%) | 10,225 (15.0%) | 954 (11.6%) |
| 2021 | 13,879 (19.1%) | 13,031 (19.1%) | 848 (10.3%) |
| 2022 | 9,579 (13.0%) | 9,233 (13.5%) | 346 (10.7%) |
| Number of conditions | |||
| 0 | 6,238 (8.2%) | 5,923 (8.7%) | 315 (3.8%) |
| 1–3 | 59,945 (78.4%) | 54,233 (79.5%) | 5,712 (69.2%) |
| ≥ 4 | 10,272 (13.4%) | 8,049 (11.8%) | 2,223 (27.0%) |
| Atrial fibrillation | 7,358 (9.6%) | 8,530 (5.5%) | 1,331 (16.1%) |
| Cardiomyopathy | 768 (1.0%) | 2,053 (1.3%) | 67 (0.8%) |
| Heart failure | 29,804 (39.0%) | 4,183 (50.7%) | 4,067 (49.3%) |
| Hypertension | 52,426 (68.6%) | 46,642 (68.4%) | 5,784 (70.1%) |
| Hemorrhagic stroke | 1,019 (1.3%) | 786 (1.2%) | 233 (2.8%) |
| Ischemic stroke | 15,677 (20.5%) | 13,183 (19.3%) | 2,494 (30.2%) |
| Pulmonary heart disease | 1,822 (2.4%) | 1,380 (2.0%) | 442 (5.4%) |
| Valvular heart disease | 4,959 (6.5%) | 4,187 (6.1%) | 772 (9.4%) |
| Chronic kidney disease | 4,348 (5.7%) | 3,418 (5.0%) | 930 (11.3%) |
| Chronic liver disease | 1,434 (1.9%) | 1,190 (1.7%) | 244 (3.0%) |
| COPD | 10,682 (14.0%) | 8,982 (13.2%) | 1,700 (20.6%) |
| Cancer | 3,385 (4.4%) | 2,475 (3.6%) | 910 (11.0%) |
| Diabetes | 25,713 (33.6%) | 22,783 (33.4%) | 2,930 (35.5%) |
| Inflammatory arthropathies | 2,891 (3.8%) | 2,485 (3.6%) | 406 (4.9%) |
| Multimorbidity phenotype | |||
| Class 1 | 40,472 (52.9%) | 37,167 (54.5%) | 3,305 (40.1%) |
| Class 2 | 29,036 (38.0%) | 25,474 (37.4%) | 3,562 (43.2%) |
| Class 3 | 6,947 (9.1%) | 5,564 (8.2%) | 1,383 (16.8%) |